GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales

Zinger Key Points

GoodRx Q4 revenue rose 1% YoY to $198.6M, missing guidance and estimates. Adjusted EPS of $0.09 missed the $0.10 consensus.
2024 prescription transactions revenue grew 5% to $577.5M, while subscription revenue fell 8% due to the Kroger Savings Club phaseout.
Every week, our Whisper Index uncovers five overlooked stocks with big breakout potential. Get the latest picks today before they gain traction.

GoodRx Holdings Inc. GDRX reported fourth-quarter revenue of $198.6 million, up slightly by 1% year over year, missing the management guidance of around $200 million and consensus of $199.75 million.

Fiscal year sales of $792.3 million came in below the guidance of around $794 million.

The company reported adjusted EPS of 9 cents, up from 8 cents a year ago, missing the consensus of 10 cents.

Q4 prescription transactions revenue increased 0.8% to $144.9 million. 2024 prescription transactions revenue increased 5% to $577.5 million, driven by an organic 7% increase in Monthly Active Consumers, including the expansion of an integrated savings program.

Also Read: How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals

GoodRx exited the fourth quarter of 2024 with over 7 million prescription-related consumers using GoodRx across prescription transactions and subscription offerings. Monthly active consumers were 6.6 million, with subscription plans of 684k.

The 2024 subscription revenue decreased by 8% to $86.5 million, primarily driven by a decrease in subscription plans due to the sunset of the partnership subscription program, Kroger Savings Club. In Q4, subscription revenue fell 10.7% to $20.68 million.

Q4 Pharma manufacturer solutions revenue jumped from $24.4 million to $28.1 million. 2024 Pharma manufacturer solutions revenue increased 26% to $107.2 million, primarily driven by organic growth as the company expands market penetration with pharma manufacturers and other customers.

Adjusted EBITDA reached $67.08 million in Q4 and $260.2 million in 2024.

Guidance: The prescription savings platform expects a fiscal year 2025 revenue outlook of $810 million—$840 million, up 2%—6% versus the consensus of $825.57 million, with adjusted EBITDA of $270 million—$286 million.

GoodRx forecasts first-quarter 2025 revenue of $201 million—$205 million, up 2%-4%, versus consensus of $202.53 million, with an adjusted EBITDA margin of about 33%.

Price Action: GDRX stock is up 4.6% at $5.12 at the last check Thursday.

Read Next: